EntryPoint Capital LLC bought a new stake in Atrion Co. (NASDAQ:ATRI – Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 197 shares of the medical instruments supplier’s stock, valued at approximately $91,000.
A number of other large investors have also recently bought and sold shares of the company. Copeland Capital Management LLC lifted its holdings in Atrion by 56.4% in the fourth quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock valued at $33,000 after acquiring an additional 31 shares during the period. Quadrant Capital Group LLC acquired a new position in Atrion in the fourth quarter valued at approximately $36,000. Harbor Investment Advisory LLC lifted its holdings in Atrion by 33.1% in the fourth quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock valued at $72,000 after acquiring an additional 47 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Atrion by 592.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock valued at $102,000 after acquiring an additional 231 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of Atrion during the 4th quarter worth approximately $108,000. Hedge funds and other institutional investors own 66.19% of the company’s stock.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on Atrion in a research note on Thursday. They set a “sell” rating for the company.
Atrion Trading Up 0.0 %
NASDAQ:ATRI traded up $0.22 during trading hours on Friday, hitting $457.87. The company had a trading volume of 4,138 shares, compared to its average volume of 23,310. The company has a 50-day moving average of $456.35 and a 200 day moving average of $413.63. The company has a market cap of $805.85 million, a P/E ratio of 43.01 and a beta of 0.68. Atrion Co. has a 1 year low of $274.98 and a 1 year high of $575.88.
Atrion (NASDAQ:ATRI – Get Free Report) last issued its earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 earnings per share (EPS) for the quarter. The company had revenue of $47.33 million during the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%.
Atrion Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Friday, June 14th were issued a dividend of $2.20 per share. This represents a $8.80 dividend on an annualized basis and a yield of 1.92%. The ex-dividend date of this dividend was Friday, June 14th. Atrion’s dividend payout ratio (DPR) is 82.71%.
About Atrion
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Recommended Stories
- Five stocks we like better than Atrion
- What Makes a Stock a Good Dividend Stock?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- 3 REITs to Buy and Hold for the Long Term
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- What Are Growth Stocks and Investing in Them
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Want to see what other hedge funds are holding ATRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atrion Co. (NASDAQ:ATRI – Free Report).
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.